Generic Xaracoll Availability
Last updated on Apr 10, 2025.
Xaracoll is a brand name of bupivacaine, approved by the FDA in the following formulation(s):
XARACOLL (bupivacaine hydrochloride - implant;implantation)
-
Manufacturer: INNOCOLL PHARMS
Approval date: August 28, 2020
Strength(s): 100MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xaracoll. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Modified collagen
Patent 11,746,141
Issued: September 5, 2023
Inventor(s): Dietrich; Alexandra et al.
Assignee(s): INNOCOLL PHARMACEUTICALS LIMITED (Athlone, IE)The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.
Patent expiration dates:
- January 9, 2033✓
- January 9, 2033
-
Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
Patent RE47826
Issued: January 28, 2020
Inventor(s): Myers Michael & Reginald Philip Wallace
Assignee(s): INNOCOLL PHARMACEUTICALS LIMITEDThe invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.
Patent expiration dates:
- May 20, 2029✓
- May 20, 2029
More about Xaracoll (bupivacaine)
- Xaracoll consumer information
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: local injectable anesthetics
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
